

RECEIVED
CENTRAL FAX CENTERDEC 04 2006
Attorney Docket No. 022052-000700US

PTO FAX NO.: (571) 273-8300

ATTENTION: Examiner J. Graser
TELEPHONE NO.: (571) 272-0858

Group Art Unit 1645

OFFICIAL COMMUNICATION**CERTIFICATION OF FACSIMILE TRANSMISSION**

I hereby certify that the following document regarding Application No. 09/844,281, filed April 30, 2001 is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

Document(s) Attached

1. Response under 37 CFR 1.116

Number of pages being transmitted, including this page: 13

Dated: December 4, 2006


Kawai Lau

*PLEASE CONFIRM RECEIPT OF THIS PAPER BY
RETURN FACSIMILE AT (415) 576-0300*

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, CA 94111-3834
Telephone: (858) 350-6100
Fax: (415) 576-0300
60930863 v1

RECEIVED
CENTRAL FAX CENTER

DEC 04 2006

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-571-273-8300 on 12/4/06.

TOWNSEND and TOWNSEND and CREW LLP

By: 
Kawar LauAMENDMENT UNDER 37 CFR 1.116
EXPEDITED PROCEDURE –
EXAMINING GROUP 1645PATENT

Attorney Docket No.: 022052-000700US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Beverly Lynn Mangold, et al.

Application No.: 09/844,281

Filed: April 30, 2001

For: ANTHRAX SPECIFIC
ANTIBODIES

Customer No.: 20350

Confirmation No. 1022

Examiner: Jennifer E. Graser

Technology Center/Art Unit: 1645

AMENDMENT UNDER 37 C.F.R. 1.116
EXPEDITED PROCEDURE EXAMINING
GROUP 1645

Mail Stop AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is in response to the "final" Office Action mailed October 3, 2006, which set January 3, 2007 as the initial deadline for response. This Reply, filed Monday, December 04, 2006, is thus believed to be timely filed within two months of October 3, 2006.

Reconsideration in light of the following revisions and remarks is respectfully requested.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 5 of this paper.